Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Pastan Website

Ira Pastan, M.D.

Selected Publications

1)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
[Journal]
2)  Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia.
J. Clin. Oncol. 30: 1822-8, 2012.
[Journal]
3)  Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I.
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.
Nature. 339: 394-7, 1989.
[Journal]
4)  Chang K, Pastan I.
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
Proc. Natl. Acad. Sci. U.S.A. 93: 136-40, 1996.
[Journal]
5)  Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, Pastan I.
A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.
Protein Eng. Des. Sel. 25: 1-6, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 12/9/2013.